PRIMA Brain-Computer Interface Reaches Commercial Availability in Europe for GA Vision Loss

PRIMA, a brain-computer interface designed to restore central vision in patients with geographic atrophy (GA), has become commercially available in Europe — the first BCI to reach that milestone, Ophthalmology Times reports.

The system targets patients who have lost central vision to geographic atrophy, the advanced dry form of age-related macular degeneration. GA progressively destroys the macula, eliminating the central visual field that patients rely on for reading, face recognition, and other fine-detail tasks. PRIMA takes a fundamentally different route from pharmacological approaches: rather than slowing degeneration, it substitutes a prosthetic pathway around the damaged retina.

The designation matters for the neurophysiology community. PRIMA is not an investigational prototype confined to trial sites; it is now a commercial medical device in the European market. That distinction places it alongside a small group of neuromodulation and neuroprosthesis technologies that have crossed from research literature into routine clinical deployment — and it marks the first time a brain-computer interface has done so for a sensory restoration indication in Europe.

The source material does not detail the full technical specification, but PRIMA's established design, as previously reported in the literature, works by pairing an implanted retinal stimulator with signal processing that converts captured images into electrical stimulation patterns. The goal is not to recreate natural vision but to generate useful artificial percepts that patients learn to interpret as central vision substitutes — a process that, as with other neuroprostheses, depends on cortical plasticity and structured rehabilitation.

For clinicians who follow implanted neurotechnology, the commercial availability raises immediate practical questions. Patient selection will be central: GA patients vary widely in the extent of atrophy, residual retinal function, and cognitive capacity to adapt to artificial percepts. Rehabilitation protocols will determine real-world outcomes, since interpreting prosthetic signals typically requires months of training. And reimbursement pathways across European health systems will shape how quickly the device moves from availability to actual adoption in ophthalmology clinics.

The milestone also carries weight beyond ophthalmology. Brain-computer interfaces have spent two decades largely in research settings — intracranial electrode arrays in epilepsy monitoring units, ECoG-based motor decoding studies, scalp-EEG neurofeedback trials. A BCI achieving commercial status for a sensory indication demonstrates a regulatory and manufacturing pathway that other neuroprosthesis programs can study. Teams working on auditory, tactile, and motor restoration BCIs now have a precedent for what a cleared, marketed implantable system looks like in the European regulatory environment.

The claim, importantly, stays within what the announcement supports. PRIMA restores a form of central visual function; it does not restore natural macular vision. How much functional benefit individual patients gain — measured in reading speed, face recognition, or activities of daily living — will emerge from post-market clinical use and any registries that follow.

Commercial availability in Europe now sets the timeline question for other markets, including U.S. regulatory status, and for the first real-world outcome data as clinics begin implanting patients outside trial protocols.